STAMFORD, Conn., Nov. 07, 2023 (GLOBE NEWSWIRE) -- Abbott Cooper PLLC is investigating Day One Biopharmaceuticals, Inc. (Nasdaq: DAWN) (“Day One” or the “Company”) on behalf of the Company’s investors. The investigation seeks to determine whether Day One’s board of directors has violated its fiduciary duty by instituting measures that impermissibly interfere with the ability of Day One stockholders to elect directors of their choosing.

康涅狄格州斯坦福德，2023年11月7日（GLOBE NEWSWIRE）-雅培库珀有限公司正在代表该公司的投资者调查第一天生物制药公司（纳斯达克股票代码：DAWN）（“第一天”或“公司”）。调查旨在通过制定不允许干扰第一天股东选择其董事的能力的措施来确定第一天的董事会是否违反了其信托责任。

Day One stockholders are encouraged to contact Abbott Cooper PLLC by calling (475) 333-0674, emailing ac@abbottlawyer.com or visiting our website at www.abbottlawyer.com for additional information about this investigation as well as their legal rights and options. Abbott Cooper PLLC is dedicated to shareholders’ rights and empowering shareholders through strategic counsel and legal advocacy.

鼓励第一天的股东通过致电（475）333-0674，电子邮件与Abbott Cooper PLLC联系ac@abbottlawyer.com或者访问我们的网站www.abbottlayer.com，了解有关此调查的更多信息以及他们的法定权利和选择。Abbott Cooper PLLC致力于股东权利，并通过战略顾问和法律宣传赋予股东权力。

For additional information about Abbott Cooper PLLC, please visit www.abbottlawyer.com. CONTACT: Abbott Cooper PLLC Abbott Cooper(475) 333-0674www.abbottlawyer.com Attorney advertising. Prior results do not guarantee a similar outcome. .

有关Abbott Cooper PLLC的更多信息，请访问www.abbottlayer.com。联系方式：Abbott Cooper PLLC Abbott Cooper（475）333-0674www.abbottlayer.com律师广告。先前的结果不能保证类似的结果。